Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single-Center, Observational Study

Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported to be safe and effective at midterm follow-up to treat drug-refractory hypertrophic obstructive cardiomyopathy in a single center. However, data from other centers are lacking. This retrospective cohort study aime...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2024-08, Vol.13 (15), p.e034080
Main Authors: Xie, Xudong, Chen, Siyuan, Cui, Yawei, Zhou, Zhenzhen, Lu, Jianhua, Du, Zhi, Ding, Jie, Xing, Kaidi, Zhang, Yuesheng, Zhou, Yijiang, Li, Jun, Guo, Xiaogang
Format: Article
Language:English
Subjects:
Adult
Aged
Cardiomyopathy, Hypertrophic - complications
Cardiomyopathy, Hypertrophic - physiopathology
Cardiomyopathy, Hypertrophic - surgery
Catheter Ablation - adverse effects
Catheter Ablation - methods
Echocardiography
Female
Follow-Up Studies
Heart Septum - diagnostic imaging
Heart Septum - surgery
Humans
hypertrophic obstructive cardiomyopathy
Male
Middle Aged
midterm follow‐up
percutaneous intramyocardial septal radiofrequency ablation
Radiofrequency Ablation - adverse effects
Radiofrequency Ablation - methods
Retrospective Studies
Time Factors
Treatment Outcome
Ventricular Function, Left
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported to be safe and effective at midterm follow-up to treat drug-refractory hypertrophic obstructive cardiomyopathy in a single center. However, data from other centers are lacking. This retrospective cohort study aimed to investigate the efficacy and safety of PIMSRA from another independent center. PIMSRA was performed in 76 patients with hypertrophic obstructive cardiomyopathy in our center from April 2020 to June 2023. The primary outcome was the reduction of left ventricular outflow tract gradient after 6 months or more post-PIMSRA. Secondary outcomes were periprocedural major adverse clinical events. Sixty-one patients returned to the hospital for follow-up 6 to 30 (median, 14) months after the procedure. At the last follow-up of the 61 patients, the maximum septal thickness decreased from a median of 23.6 (interquartile range, 20.5-26.4) to 19.1 (interquartile range, 16.0-22.1) mm (
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.123.034080